英文摘要

查看全文 下载全文     

英文摘要

查看全文 下载全文     

2009年上海地区细菌耐药性监测

Soriano A,Marco F,Martinez JA,et al.Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia[J].Clin Infect Dis,2008,46(2):193-200.

Sun W,Chen H,Liu Y,et al,Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China?[J].Antimicrob Agents Chemother,2009,53(9):3642-3649.

Clinical and Laboratory Standads Institute.Performance Standards for Antimicrobial Susceptibility Testing[S].Eighth Informational Supplement,1998,M100-S8.

Clinical and Laboratory Standads Institute.Performance Standards for Antimicrobial Susceptibility Testing[S].Sixteenth Informational Supplement,2006,M100-S16.

Lahey Clinic.Amino acid sequences for TEM,SHV and OXA extended-spectrum and inhibitor-resistant β-lactamases[EB/OL].URL:http://www.lahey.org/studies/webt.asp.

Clinical and Laboratory Standads Institute.Performance Standards for Antimicrobial Susceptibility Testing[S].Twentieth Informational Supplement,2010,M100-S20.

沈继录,朱德妹,吴卫红,等.革兰阴性杆菌碳青霉烯酶产生与细菌耐药性关系的研究[J].中华检验医学杂志,2008,31(4):408-414.

Clinical and Laboratory Standads Institute.Performance Standards for Antimicrobial Susceptibility Testing[S].Twentieth Informational Supplement(June 2010 Update),2010,M100-S20-U.

>>更多...     

抗肿瘤血管生成在淋巴瘤治疗领域的研究进展

Wang ES,Temya-Feldslein J,Wu Y,et al.Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.Blood,2004,104:2893-2902.

Elezkurtaj S,Kopitz C,Baker AH,et al.Adenovirus-mediated overexpression of tissue inhibitor of metallopmteinases-1 in the liver:efficient protection against T-cell lymphoma and colon carcinoma metastasis.J Gene Med,2004,6:1228-1237.

Kruger A,Arit MJ,Gerg M,et al.Antimetastalic activity of a novel mechanism-based gelatinase inhibitor.Cancer Res,2005,65:3523-3526.

O'Reilly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth.Cell,1997,88:277-285.

Abdollahi A,Hahnfehh P,Macrcker C,et al.Endostatin's antiangiogenic signaling network.Mol Cell,2004,13:649-663.

Carmeliet P.Angiogenesis in life,disease and medicine.Nature,2005,438:932-936.

Ribatti D.Judah Folkman,a pioneer in the study of angiogenesis.Angiogenesis,2008,11:3-10.

Li ww,Hutnik M,Gehr G.Anfiangiogenesis in haematological malignancies.Br J Haematol,2008,143:622-631.

Wolpin BM,Mayer RJ.Systemic treatment of coloreetal cancer.Gastroenterology,2008,134:1296-1310.

Dong X,Han ZC.Yang R,et al.Angiogenesis and antiangiogenic therapy in hematologic malignancies.Crit Rev Oncol Hematol,2007.62:105-118.

Giatromanolaki A,Koukourakis MI,Pezzella F,et al.Pbosphorylated VEGFR2/KDR receptors are widely expressed in B-cell nonHodgkin's lymphomas and correlate with hypoxia inducible factor activation.Hematol Oncol,2008,26:219-224.

Folkman J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action.Exp Cell Res,2006,312:594-607.

Bertolini F,Fusetti L,Mancuso P,et al.Endostatin,an antiangiogenie drug,induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human highgrade non-Hodgkin lymphoma.Blood,2000,96:282-287.

Ling Y,Yang Y,Lu N,et al.Endostar,a novel recombinant human endostatin.exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.Biochem Biophys Res Commun,2007,361:79-84.

王金万,孙燕,刘永煜,等.重组人血管内皮抑索联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究.中国肺癌杂志,2005,8:283-290.

>>更多...     

人血小板抗原检测及其在胎儿新生儿同种免疫血小板减少症中的应用

2006(zl)

2.0.TX;2-3.aspx'>Establishment of an HPA-1-to-16-typed platelet donor registry in China [其它论文] 2006(05)

Human platelet antigen genotyping by using sequence-specific primers and the particle gel agglutination assay 2005(04)

2.0.TX;2-N.aspx'>Real-time quantitative PCR assay for analysis of platelet glycoprotein Ⅲ a gene expression [其它论文] 2005(03)

Ficko T.Galvani V.Rupreht R Real-time PCR genotyping of human platelet alloantigens HPA-1,HPA-2,HPA-3 and HPA-5 is superior to the standard PCR-SSP method [其它论文] 2004(06)

Liu TC.Shih MC.Lin CL Gene frequencies of the HPA-1 to HPA-8w platelet antigen alleles in Taiwanese,Indonesian,and Thai [其它论文] 2002(05)

Higgins M.Hughes A.Buzzacott N High-throughput genotyping of human platelet antigens using the 5'-nuclease assay and minor groove binder probe technology [其它论文] 2004(02)

Bres JC.Merieux Y.Dugas V New method for DNA microarrays development:applied to human platelet antigens polymorphisms [其它论文] 2005(02)

卞茂红.刘淼.杨鹏 多重聚合酶链反应-微流芯片检测人血小板抗原系统基因型方法的建立与应用 [其它论文] -中华检验医学杂志2006(07)

Metcalfe P.Allen D.Kekomaki R 29th International Congress of the International Society of Blood Transfusion:HPA genotyping-where are mistakes made 2006(z2)

Mohanty D.Kulkarni B.Ghosh K Human platelet specific antigens and their importance 2004(08)

Andrei-Selmer C.Socher I.Bein G 29th International Congress of the International Society of Blood Transfusion:real-time analysis of HPA-la antigen-antibody interaction by surface plasmon resonance technology 2006(z2)

Castro V.Kroll H.Origa AF A prospective study on the prevalence and risk factors for neonatal thrombocytopenia and platelet alloimmunization among 9332 unselected Brazilian newborns [其它论文] 2007(01)

Ohto H.Miura S.Ariga H The natural history of maternal immunization against foetal platelet alloantigens [其它论文] 2004(06)

Kroll H.Yates J.Santoso S Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event:characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens [其它论文] 2005(03)

Mandelbaum M.Koren D.Eichelberger B Frequencies of maternal platelet alloantibodies and autoantibodies in suspected fetal/neonatal alloimmune thrombocytopenia,with emphasis on human platelet antigen-15 alloimmunization [其它论文] 2005(01)

Killie MK.Husebekk A.Kaplan C Maternal human platelet antigen-la antibody level correlates with the platelet count in the newborns:a retrospective s tudy [其它论文] 2007(01)

Bertrand G.Martageix C.Jallu V Predictive value of sequential maternal anti-HPA-la antibody concentrations for the severity of fetal alloimmune thrombocytopenia [其它论文] 2006(03)

Ghevaert C.Campbell K.Stafford P HPA-la antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia [其它论文] 2007(07)

>>更多...     

太极拳锻炼周期对原发性高血压的血压及心血管危险因素的影响:系统性评价和Meta分析

目的 采用Meta分析系统性评价太极拳锻炼持续周期是否影响原发性高血压患者的治疗效果,为原发性高血压患者提供合理的运动干预方案。方法 检索从中国知网、万方数据库、PubMed、Cochrane Library、Science Direct、Web Of Science等电子数库中关于太极拳对原发性高血压治疗效果的随机对照试验,采用RevMan 5.3软件进行Meta分析。结果 最终筛选21篇文献,总计有2 129名参与者。Meta分析结果提示:与对照组相比太极拳锻炼持续周期12周以上更有利于收缩压[M D=-10.20,95% C I(-14.57,-5.83)]和舒张压[M D=-5.12,95% C I(-7.63,-2.60)]水平的降低;能提高原发性高血压患者NO含量[M D=6.87,95% C I(4.83,8.90)];改善高血压患者除HDL-C之外的血脂代谢水平:TC[M D=-0.51,95% C I(-0.69,-0.33)]、TG[M D=-0.72,95% C I(-1.09,-0.36)]、LDL-C[M D=-0.59,95% C I(-0.87,-0.32)]。亚组分析结果提示运动频率≥5次/周、运动时间<60 min/d有较好的降压效果。结论 Meta分析表明,与其他持续周期相比,太极拳锻炼持续周期12周以上,每次运动时长控制在60 min以内,每周运动5次以上对降低血压水平、提高NO含量,改善血脂代谢效果最为明显,应值得在临床上推广。     

糖皮质激素对晚期肿瘤患者免疫疗效影响的Meta分析

目的 探讨糖皮质激素(glucocorticoid, GC)的使用对接受免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)治疗的肿瘤患者的总生存期(overall survival, OS)和无进展生存期(progression-free survival, PFS)的影响。方法 使用PubMed、Wiley、Web of Science和Cochrane Library数据库检索2020年10月以前发表的有关肿瘤患者在接受ICIs治疗期间,GC使用对患者预后影响的文献,采用Review Manager 5.3软件和Stata14.0软件进行统计分析。结果 总共有23篇文献被纳入荟萃分析,Meta分析结果显示在晚期肿瘤患者接受ICIs治疗期间,GC的使用是死亡(H R=1.54, 95% C I=1.29~1.83)和疾病进展(H R=1.82, 95% C I=1.36~2.43)的危险因素。此外,亚组分析结果显示,GC用于缓解脑水肿、癌痛等肿瘤相关并发症时会增加患者死亡(H R=2.14, 95% C I=1.62~2.81)和疾病进展(H R=2.26,95% C I=1.72~2.96)的风险。然而,GC被用于处理免疫相关不良反应(immune-related adverse events,irAEs)等非肿瘤相关性并发症,GC的使用与未使用或者小剂量(<10 mg/d)使用相比差异无统计学意义(P>0.05)。结论 当GC用于处理肿瘤相关性并发症时,GC的使用对接受免疫治疗的肿瘤患者的预后会造成负面影响。     

电视辅助胸腔镜外科

１概述 电视辅助胸腔镜外科（Ｖｉｄｅｏ—ａｓｓｉｓｔｅｄ ＴｈｏｒａｃｉｃＳｕｒｇｅｒｙ,ＶＡＴＳ）是内镜外科在设备和手术器械不断发展的基础上产生的“微侵入”外科技术。如腹腔镜技术在外科的应用一样,９０年代以来,ＶＡＴＳ在胸外科领域也得到蓬勃发展。 ＶＡＴＳ的出现改变了胸腔内镜技术的面貌。早在１９１０年,瑞士内科医师Ｊａｃｏｂｅｕｓ首先把膀胱镜技术移植到胸腔内,用于诊断胸膜病灶以及应用到治疗肺结核的胸膜粘连术和肺萎陷疗法。开辟了内镜诊断、治疗胸部疾病的先例［１］。以后,在２０世纪三四十年代,逐渐发…     

Alpha(4)beta(7)/alpha(4)beta(1) dual integrin antagonists block alpha(4)beta(7)-dependent adhesion under shear flow

The alpha(4) integrin, alpha(4)beta(7), plays an important role in recruiting circulating lymphocytes to the gastrointestinal tract, where its ligand mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is preferentially expressed on high endothelial venules (HEVs). Dual antagonists of alpha(4)beta(1) and alpha(4)beta(7), N-(2,6-dichlorobenzoyl)-(L)-4-(2',6'-bis-methoxyphenyl)phenylalanine (TR14035) and N-(N-[(3,5-dichlorobenzene)sulfonyl]-2-(R)-methylpropyl)-(D)-phenylalanine (compound 1), were tested for their ability to block the binding of alpha(4)beta(7)-expressing cells to soluble ligand in suspension and under in vitro and in vivo shear flow. Compound 1 and TR14035 blocked the binding of human alpha(4)beta(7) to an (125)I-MAdCAM-Ig fusion protein with IC(50) values of 2.93 and 0.75 nM, respectively. Both compounds inhibited binding of soluble ligands to alpha(4)beta(1) or alpha(4)beta(7) on cells of human or rodent origin with similar potency. Under shear flow in vitro, TR14035 and compound 1 blocked binding of human alpha(4)beta(7)-expressing RPMI-8866 cells or murine mesenteric lymph node lymphocytes to MAdCAM-Ig with IC(50) values of 0.1 and 1 microM, respectively. Intravital microscopy was used to quantitate alpha(4)-dependent adhesion of fluorescent murine lymphocytes in Peyer's patch HEVs. When cells were prestimulated with 2 mM Mn(2+) to activate alpha(4)beta(7) binding to ligand, anti-alpha(4) monoclonal antibody (mAb) [10 mg/kg (mpk) i.v.] blocked adhesion by 95%, and anti-beta(1) mAb did not block adhesion, demonstrating that this interaction was dependent on alpha(4)beta(7). TR14035 blocked adhesion to HEVs [ED(50) of 0.01-0.1 mpk i.v.], and compound 1 blocked adhesion by 47% at 10 mpk i.v. Thus, alpha(4)beta(7)/alpha(4)beta(1) antagonists blocked alpha(4)beta(7)-dependent adhesion of lymphocytes to HEVs under both in vitro and in vivo shear flow.     

(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)

(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU, Brivudin, Zostex, Zerpex, Zonavir), now more than 20 years after its discovery, still stands out as a highly potent and selective inhibitor of herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV) infections. It has been used in the topical treatment of herpetic keratitis and recurrent herpes labialis and the systemic (oral) treatment of herpes zoster (zona, shingles). The high selectivity of BVDU towards HSV-1 and VZV depends primarily on a specific phosphorylation of BVDU to its 5'-diphosphate (DP) by the virus-encoded thymidine kinase (TK). After further phosphorylation (by cellular enzymes), to the 5'-triphosphate (TP), the compound interferes as a competitive inhibitor/alternate substrate with the viral DNA polymerase. The specific phosphorylation by the HSV- and VZV-induced TK also explains the marked cytostatic activity of BVDU against tumor cells that have been transduced by the viral TK genes. This finding offers considerable potential in a combined gene therapy/chemotherapy approach for cancer. To the extent that BVDU or its analogues (i.e., BVaraU) are degraded (by thymidine phosphorylase) to (E)-5-(2-bromovinyl)uracil (BVU), they may potentiate the anticancer potency, as well as toxicity, of 5-fluorouracil. This ensues from the direct inactivating effect of BVU on dihydropyrimidine dehydrogenase, the enzyme that initiates the degradative pathway of 5-fluorouracil. The prime determinant in the unique behavior of BVDU is its (E)-5-(2-bromovinyl) substituent. Numerous BVDU analogues have been described that, when equipped with this particular pharmacophore, demonstrate an activity spectrum characteristic of BVDU, including selective anti-VZV activity.     

真空负压吸引在乳腺癌改良根治术后应用的研究

目的 ：探讨Drainobag真空负压引流瓶在乳腺癌根治术后的应用效果。方法：对66 例在我科施行乳腺癌改良根治术的患者,术后随机分为两组,对照组(33 例)选择持续墙式中心负压吸引引流,改进组(33例)应用Drainobag真空负压引流瓶引流,对两组术后第一天引流量、置管时间、皮下积液、皮瓣坏死和术后住院时间进行比较。结果：改进组术后第一天引流量、置管时间、皮下积液、皮瓣坏死率和术后住院时间均明显低于对照组(Ｐ＜0.05)。结论：应用Drainobag真空负压引流瓶引流效果好,能有效预防术后并发症的发生,缩短了住院时间,增强了病人的自信心。     

Alendronate (Fosamax) and risedronate (Actonel) revisited

A 10-year study of daily oral alendronate (Fosamax) and a 7-year study of daily oral risedronate (Actonel) indicate that both drugs maintained increases in bone mineral density (BMD) and decreases in markers of bone remodeling throughout the study period. Both drugs are now more commonly taken once weekly. Available data are insufficient to compare fracture rates with alendronate and risedronate, and fracture rates are considered the most important endpoint in osteoporosis studies. Recent reports of severe pain and jaw osteonecrosis with these drugs are disturbing.